Ownership and insider activity for NRx Pharmaceuticals, Inc. (NRXP): insider transactions, US Senate and House trading disclosures and shares outstanding. Track how corporate insiders and politicians are trading the stock.
NRx Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical firm focused on developing innovative therapies for disorders of the central nervous system and critical lung diseases. Its product portfolio features ZYESAMI, an experimental medication that has successfully completed Phase IIb/III clinical trials for treating respiratory failure associated with COVID-19.
Price
| Price | $3.35 |
| Market Cap | $58M |
| Exchange | NASDAQ |
| Country | US |
Recent Insider Transactions
| Date | Insider | Type | Shares | Value |
|---|---|---|---|---|
| 2026-01-27 | Casper Joseph Michael | A-Award | 100,000 | $239K |
| 2026-01-27 | Casper Joseph Michael | 100,000 | $239K | |
| 2025-04-09 | Javitt Jonathan C | A-Award | 125,000 | $216K |
| 2025-04-09 | McBride Dennis | A-Award | 25,000 | $43K |
| 2025-04-09 | Hurvitz Chaim | A-Award | 25,000 | $43K |
| 2025-04-09 | Flynn Patrick John | A-Award | 50,000 | $86K |
| 2025-08-18 | B Group, Inc. | |||
| 2025-02-07 | ABRAMS MICHAEL S | A-Award | 50,000 | $147K |
| 2024-12-17 | Javitt Jonathan C | P-Purchase | 40,000 | $47K |
| 2024-11-18 | ABRAMS MICHAEL S |
Balance Sheet (10y)
| Year | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $449374 | $11079 | $6 | $1.9M | $27.6M | $20.1M | $4.6M | $1.4M | $7.8M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | $831000 | 0 | $7000 | $6000 | 0 | $161000 |
| Inventory | 0 | 0 | 0 | $214000 | 0 | 0 | 0 | 0 | 0 |
| Total Current Assets | $536376 | $30193 | $69489 | $2.9M | $32.7M | $25.8M | $6.9M | $3.3M | $8.9M |
| Property, Plant & Equipment | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $633000 |
| Goodwill | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $1.8M |
| Intangible Assets | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | $925000 |
| Total Assets | $69.6M | $70.8M | $32.1M | $2.9M | $32.7M | $25.8M | $7.3M | $3.7M | $13.0M |
| Accounts Payable | $85671 | $551099 | 0 | $3.2M | $3.7M | $2.1M | $4.6M | $4.1M | $4.3M |
| Short-term Debt | 0 | 0 | 0 | $249000 | $518000 | $7.7M | $9.2M | $1.6M | 0 |
| Total Current Liabilities | $93171 | $567410 | $622441 | $46.2M | $11.9M | $15.6M | $19.0M | $21.9M | $28.6M |
| Long-term Debt | 0 | $690000 | $2.0M | $548000 | 0 | $2.8M | 0 | $5.0M | 0 |
| Total Liabilities | $93171 | $1.3M | $2.6M | $46.7M | $11.9M | $18.4M | $19.0M | $26.9M | $28.9M |
| Retained Earnings | -$105033 | -$38932 | $369495 | -$90.2M | -$183.2M | -$223.0M | -$253.1M | -$278.3M | -$306.9M |
| Total Equity | $69.5M | $69.5M | $29.5M | -$43.8M | $20.8M | $7.4M | -$11.7M | -$23.2M | -$15.9M |
| Total Debt | 0 | $690000 | $2.0M | $797000 | $518000 | $10.5M | $9.2M | $6.6M | $631000 |
| Net Debt | -$449374 | $678921 | $2.0M | -$1.1M | -$27.1M | -$9.5M | $4.6M | $5.1M | -$7.2M |
| Working Capital | $443205 | -$537217 | -$552952 | -$43.2M | $20.8M | $10.2M | -$12.2M | -$18.6M | -$19.7M |
Financial Health
| Debt / Equity | -7.33 |
| Current Ratio | 0.86 |
Profitability
| Return on Equity | 168.68% |
| Return on Invested Capital | -1855.48% |
| Return on Assets | -68.74% |
| Gross Margin | 32.68% |
| Operating Margin | -588.24% |
| Net Margin | -691.81% |
Related companies: COEP · CUE · EQ · HOWL · IOBT · IPSC · KPTI
Explore sector: Healthcare · Biotechnology
More sections of NRXP: Overview · Financials · Valuation · Statistics · Estimates · Technical · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks